KDR and non-small cell lung carcinoma: The anti‐VEGFR2 antibody ramucirumab has been approved in combination with docetaxel for the second‐line treatment of NSCLC, including lung SCC, based on the Phase III REVEL trial.36 The ErbB‐family blocker afatinib has demonstrated clinical activity in patients with lung SCC.10, 37, 38 Afatinib significantly improved the PFS, OS, and DCR vs erlotinib in the LUX‐Lung 8 trial,39 leading to its approval for locally advanced or metastatic lung SCC who had progressed after platinum‐based chemotherapy.